Efficacy and safety of Combination therapy of Hepatic Arterial Embolization and chemotherapy for the treatment of patients with metastatic neuroendocrine tumors

Kato Hironari0 个研究点目标入组 18 人开始时间: 2021年6月21日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1 Patients who diagnosed with non-functionnal GEP-NEN of which grade was G1 confirmed pathologically
•2 Patients with liver metastatic tumors who have no treatment history of TAE and chemotherapy
•3 20 age old over
•4 Patienst who have been fully informed consent
•5 Regardless of gender
•6 Less than 1 of performance status
•7 Adequate hematologic and end-organ function

•1 Tumor thrombus or thrombus in the main and/or first portal vein
•2 Moderate or severe ascites
•3 Severe arteriovenous shunt in the liver
•4 Allergy for contrast media
•5 Less than 30 mL/min of eGFR
•6 Allergy for Everolimus, Sirolimus and Sirolimus derivatives
•7 Allergy for gelatin
•8 Prior treatment with mTOR inhibitor
•9 Long treatment with corticosteroids or other immunostimulatory agents
•10 Significant cardiovascular, infectious, diabate or plumonary disease
•11 The participant has a fasting glycemic level of 1.5 ULN or higher at the start of the screening period
•12 Patients who diagnosed as Interstitial pneumonia by CT
•13 Being pregnant or possibly pregnant
•14 Patients who judged as not suitable for chemotherapy
•15 Patients who judged as inappropriate candidate by the chief medical examine

发起方

Kato Hironari